BioVaxys Announces Application for Management Cease Trade Order

Core Viewpoint - BioVaxys Technology Corp. has announced a delay in filing its annual financial statements and related documents for the year ended October 31, 2025, due to changes in its accounting systems and processes, with an expected completion date for the filings by April 28, 2026 [1][2][4]. Group 1: Filing Delay and Management Cease Trade Order - The company was unable to meet the February 28, 2026 deadline for its annual filings due to a late start in the audit process [2]. - A temporary management cease trade order (MCTO) was granted by the British Columbia Securities Commission, effective March 3, 2026, prohibiting trading in the company's securities by its CEO and CFO [3]. - The MCTO will remain in effect until the annual filings are completed, and the company will issue bi-weekly default status reports as required [4]. Group 2: Company Overview and Clinical Pipeline - BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for various diseases, including cancers and allergies, using its DPX™ immune-educating technology platform [6]. - The company's clinical pipeline includes maveropepimut-S (MVP-S), currently in phase IIB development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum-resistant Ovarian Cancer, which has shown clinical benefits and a targeted immune response [6]. - Other developments include DPX™+SurMAGE for dual-targeted immunotherapy, DPX™-RSV for Respiratory Syncytial Virus, and BVX-0918, a personalized vaccine for late-stage ovarian cancer [6].